Frontlight ResearchEarly access
Taking people in United StatesPhase 1
Tests LY4584180 in adults with previously treated blood cancers
Tests LY4584180 in adults with lymphoma that returned after earlier treatment.
Key facts
- Who runs it
- Eli Lilly and Company
- Where
- Atlanta, Boston, Columbus, Dallas, Denver, Duarte, Houston, Los Angeles, Miami, Milwaukee, Nashville, New York, Portland, Rochester, San Francisco, Sarasota, Scottsdale, and Seattle, United StatesSee the 21 sitesAlso in 7 other countries, 24 sites
- Trial code
- Registry title
- A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 460 people, planned
- Started
- 17 Apr 2026
- Expected to end
- Feb 2030
- Type of study
- Interventional, 4 groups
- Treatments tested
- LY4584180
- Rituximab
- Record updated
- 4 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with certain B-cell lymphomas who were treated before and have measurable disease.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Diffuse large B-cell lymphoma, high-grade B-cell lymphoma, transformed lymphoma, follicular large B-cell lymphoma, follicular lymphoma or other non-Hodgkin lymphoma, with measurable disease.
- Earlier treatment
- At least 2 prior lines of systemic therapy, or not able to have the available therapy. All earlier cancer treatment must be stopped and the person recovered from its immediate effects.
Main reasons for not taking part
- An active second cancer
- Known lymphoma in the central nervous system (some exceptions need the investigator and sponsor approval)
- Known Cytomegalovirus infection
- Known hepatitis B or C infection or uncontrolled HIV
- Known significant heart disease
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Has been treated for the following blood cancers and has received at least 2 prior lines of systemic therapy or not eligible for available therapy:; Diffuse large B-cell lymphoma - not otherwise specified; High-grade B-cell lymphoma; Diffuse large B-cell lymphoma - transformed from indolent lymphomas; Follicular large B-cell lymphoma; Follicular lymphoma; Other non-Hodgkin lymphoma
- Has measurable disease
- Has discontinued all previous treatments for cancer and has recovered from the immediate effects of therapy
Who cannot take part
- Has known central nervous system (CNS) involvement by systemic lymphoma. Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of active CNS disease may be eligible and enrolled if a compelling clinical rationale is provided by the Investigator and with documented Sponsor approval
- Has an active second cancer
- Has known Cytomegalovirus infection. Participants with negative status are eligible
- Has known hepatitis B or C infection or uncontrolled HIV
- Has known significant heart disease
Where in United States
Also in 7 other countries, 24 sites
- Emory University HospitalAtlanta, United StatesTaking people
- Dana-Farber Cancer InstituteBoston, United StatesTaking people
- Massachusetts General HospitalBoston, United StatesTaking people
- The Ohio State University (OSU)Columbus, United StatesTaking people
- Texas Oncology - DFW (Sammons CC)Dallas, United StatesTaking people
- Colorado Blood Cancer InstituteDenver, United StatesTaking people
- City of HopeDuarte, United StatesTaking people
- Baylor College of MedicineHouston, United StatesNot yet recruiting
- University of California, Los Angeles (UCLA) - Medical CenterLos Angeles, United StatesTaking people
- University of Miami - Sylvester Cancer CenterMiami, United StatesTaking people
- Froedtert Hospital and the Medical College of WisconsinMilwaukee, United StatesTaking people
- Sarah Cannon Research InstituteNashville, United StatesTaking people
- Vanderbilt University Medical CenterNashville, United StatesTaking people
- Columbia UniversityNew York, United StatesTaking people
- Oregon Health & Science University (OHSU)Portland, United StatesNot yet recruiting
- Mayo Clinic - RochesterRochester, United StatesTaking people
- University of RochesterRochester, United StatesTaking people
- University of California San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer CenterSan Francisco, United StatesTaking people
- Florida Cancer Specialists - SarasotaSarasota, United StatesTaking people
- Mayo Clinic ScottsdaleScottsdale, United StatesTaking people
- University of Washington - Fred Hutchinson Cancer Center (Seattle Cancer Care Alliance)Seattle, United StatesTaking people
About the trial
What the trial wants to find out
The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers. For each participant, the study could last about 9 months or possibly longer including screening.
The 4 groups in the trial
- Phase 1a-Monotherapy Dose Escalation (Cohort A1)Treatment being tested
LY4584180 monotherapy administered orally
Treatment: LY4584180
- Phase 1a-Monotherapy Dose Optimization (Cohort A2)Treatment being tested
LY4584180 monotherapy administered orally
Treatment: LY4584180
- Phase 1b-Dose Expansion-Monotherapy (Cohort B1-B3)Treatment being tested
LY4584180 monotherapy administered orally
Treatment: LY4584180
- Phase 1b-Dose Expansion-Combination (Cohort B4)Treatment being tested
LY4584180 administered orally in combination with rituximab administered through IV infusion
Treatment: LY4584180 and Rituximab
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
- Official title
- NOVA-BCL6-1, A First-in-Human, Multicenter Phase 1a/1b Study to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of LY4584180 in Adult Participants With Previously Treated Hematologic Malignancies
- Plain-language title
- Tests LY4584180 in adults with previously treated blood cancersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 4 November 2026